BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 14, 2019
View Archived Issues
Making chemo worse for cancer, better for heart
Read More
Making jumping genes sit still could be antiaging strategy
Read More
Exelixis begins phase I development with tyrosine kinase inhibitor XL-092
Read More
Kodiak Sciences looks to phase II with KSI-301 for retinal diseases
Read More
Phase I results demonstrate clinical proof of mechanism for SJX-653
Read More
Alphabet soup: multiple pancreatic cell types can be reprogrammed into 'pseudoislets'
Read More
Enrollment ongoing in phase I study of NUC-7738 in patients with advanced solid tumors or lymphoma
Read More
Affinivax initiates phase I/II study ASP-3772
Read More
Catalyst Biosciences presents data from MAA-201 study of MarzAA
Read More
Phase I safety and pharmacokinetics data presented for LCB01-0371
Read More
Researchers present novel vaginal rings designed for sustained delivery of 5P12-RANTES
Read More
DNA-based Mayaro virus vaccine protects mice from virus challenge
Read More
Discovery of VU-2957, a novel metabotropic glutamate mGlu4 receptor PAM
Read More
Cyclin D1 deficiency in SCCOHT confers high susceptibility to CDK4/6 inhibitors
Read More
ARHGEF1 loss found to cause a type of primary antibody deficiency
Read More
Nimbus Lakshmi discloses new TYK2 inhibitors
Read More
Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent HBV capsid assembly inhibitors
Read More
FDA approves Egaten for fascioliasis
Read More
Sanofi discovers antimycobacterial compounds
Read More
Abilita Bio enters into multitarget research collaboration agreement with Amgen
Read More
Chengdu Di'ao Pharmaceutical Group presents new proteasome inhibitors
Read More
Caladrius reports 1-year data from phase IIa trial of CLBS-03 in recent onset type 1 diabetes
Read More
Hepagene Therapeutics identifies inhibitor of apoptosis proteins (IAP) inhibitors
Read More
FDA issues complete response letter for iclaprim NDA in ABSSSI
Read More
Addex and Indivior intend to accelerate additional GABA-B PAM compounds for addiction
Read More
FDA clears IND for phase II study of LPCN-1144 in biopsy-confirmed NASH
Read More